VIDEO: Faricimab shows greater reduction in hard exudates in patients with DME

ByRoger A. Goldberg, MD, FACS

ByAnthony DeFino

ByEamon N. Dreisbach

Fact checked byChristine Klimanskis, ELS

SEATTLE — In this Healio Video Perspective from the ARVO meeting, Roger A. Goldberg, MD, MBA, discusses an analysis examining the resolution of hard exudates in patients with diabetic macular edema treated with faricimab vs. aflibercept.

A post hoc analysis of data from the phase 3 YOSEMITE and RHINE trials showed “about a 10% absolute reduction in the proportion of patients who have hard exudates at year 1 and year 2 when treated with faricimab,” he said.

Published by:

Sources/Disclosures

Collapse

Source:

Goldberg RA, et al. Greater reduction in hard exudates with faricimab vs aflibercept in patients with DME: Biomarker results from the phase 3 YOSEMITE/RHINE trials. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.

Disclosures: Goldberg reports being an investigator and consultant for Genentech, Regeneron and Roche.

Read more

VIDEO: Faricimab shows greater reduction in hard exudates in patients with DME

Related Content